RCUS Arcus Biosciences Inc.

9.86
+0.48  (+5%)
Previous Close 9.38
Open 9.14
Price To Book 2.55
Market Cap 452,169,503
Shares 45,858,976
Volume 49,746
Short Ratio 14.39
Av. Daily Volume 101,770
Stock charts supplied by TradingView

NewsSee all news

  1. Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers

    Collaboration leverages Genentech's MORPHEUS studies to accelerate development of AB928, a potential best-in-class therapy targeting the adenosine axis to stimulate immune responses against cancer Arcus Biosciences,

  2. Arcus Biosciences Announces Third Quarter 2019 Financial Results and Recent Corporate Updates

    Demonstrated best-in-class potential of AB928, a selective adenosine receptor antagonist that efficiently blocks both A2a and A2b receptors, as evidenced by a favorable safety profile when combined with multiple

  3. Arcus Biosciences Appoints Internationally Distinguished Physician-Scientist, Antoni Ribas, M.D., Ph.D., to Board of Directors

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Antoni Ribas, M.D., Ph.D. has joined the Company's Board of

  4. Arcus Biosciences to Present Updated Data from the Phase 1 Safety Dose-Escalation Portion of the AB928 Combination Trials at the European Society for Medical Oncology (ESMO) Meeting

    Company to participate in poster display session on September 30, 2019 at 12:00pm CEST Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies,

  5. Arcus Biosciences to Present at the 2019 Cantor Global Healthcare Conference

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will present at the 2019

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 dose-expansion cohort to be initiated mid-2019.
AB122
Healthy volunteers
Phase 1 initiation announced September 4, 2019.
AB298 + IPI-549 + Doxil
Triple negative breast cancer (TNBC) and ovarian cancer
Phase 1 expansion data due from mid-2020.
AB928 + mFOLFOX
Colorectal Cancer
Phase 1b expansion data due from mid-2020.
AB928 + AB122
Solid tumors
Phase 1 safety data due mid-2020.
AB154 + AB122
Solid tumors
Phase 1 expansion data due mid-2020, randomized data 4Q 2020.
AB680 + AB122
Pancreatic Cancer

Latest News

  1. Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers

    Collaboration leverages Genentech's MORPHEUS studies to accelerate development of AB928, a potential best-in-class therapy targeting the adenosine axis to stimulate immune responses against cancer Arcus Biosciences,

  2. Arcus Biosciences Announces Third Quarter 2019 Financial Results and Recent Corporate Updates

    Demonstrated best-in-class potential of AB928, a selective adenosine receptor antagonist that efficiently blocks both A2a and A2b receptors, as evidenced by a favorable safety profile when combined with multiple

  3. Arcus Biosciences Appoints Internationally Distinguished Physician-Scientist, Antoni Ribas, M.D., Ph.D., to Board of Directors

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Antoni Ribas, M.D., Ph.D. has joined the Company's Board of

  4. Arcus Biosciences to Present Updated Data from the Phase 1 Safety Dose-Escalation Portion of the AB928 Combination Trials at the European Society for Medical Oncology (ESMO) Meeting

    Company to participate in poster display session on September 30, 2019 at 12:00pm CEST Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies,

  5. Arcus Biosciences to Present at the 2019 Cantor Global Healthcare Conference

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will present at the 2019